Fla. Hospital Again Denied Cert. In $867M Drug Antitrust Suit
A Florida federal judge on Monday again refused to grant class certification of an $867 million antitrust class action accusing Astellas Pharma Inc. of improperly requiring use of its Adenoscan drug...To view the full article, register now.
Already a subscriber? Click here to view full article